Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins

Contributed by: PR Newswire

Tags

Camurus

More Like This

PR Newswire associated0

Cambrex Announces Strategic Agreement with Lilly to Support Biotech Collaborator Manufacturing

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

PR Newswire associated0

Amacathera Collaborates With Leading Global Pharmaceutical Company To Develop Single-Injection, Long-Acting Biologic Using Its Advanced Hydrogel Delivery Platform, Amacagel™

Camurus' POSITANO study shows treatment effects with CAM2029 in polycystic liver disease patients

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

Lindy Biosciences Enters Licensing and Collaboration Agreement With Novartis for Multi-target Drug Delivery Innovation

PR Newswire associated0

KeyBioscience Announces Extension of Strategic Collaboration with Lilly

PR Newswire associated0

NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), PRESENTING PATIENT DATA AND PATIENT EXPERIENCE STUDY FOR LACRIFILL® CANALICULAR GEL, A NOVEL THERAPY FOR DRY EYE, AT THE AMERICAN SOCIETY OF CATARACT AND REFRACTIVE SURGERY ANNUAL MEETING